![Featured Image](https://vumc-reporter.s3.amazonaws.com/uploads/reporter_101102_10.jpg)
Dr. David Miller and colleagues have cloned and characterized the unc-4 gene and the protein it encodes. UNC-4 is a transcription factor that works in the cell nucleus to turn other genes "off." (photo by Neil Brake)
The Eli Lilly Lectureship in Psychopharmacology, a new lectureship to support an annual visiting professor to the department of Psychiatry, will be held Oct. 15 at 11:10 a.m. in 208 Light Hall.
Chris Fibiger, Ph.D., will be this year’s distinguished speaker. Fibiger is vice president of Neuroscience Discovery Research and Clinical Investigation at Lilly Research Laboratories. He is responsible for Lilly’s worldwide Neuroscience discovery efforts, ranging from early exploratory research through Phase II clinical trials. Fibiger is also responsible for evaluating and implementing collaborative efforts, external alliances and licensing agreements with biotechnology companies and academic institutions.
Fibiger previously served as professor and head of the division of Neurological Sciences at the University of British Columbia in Vancouver. He is a Fellow of the American College of Neuropsychopharmacology (ACNP) and serves on its Council. Having served on the editorial board of 10 journals in the field of neuroscience, he also is coeditor of Neuropsychopharmacology. His many scientific papers focused primarily on the neurobiological substrates of Alzheimer’s disease, schizophrenia, depression, and drug abuse.